Continuous Oral Contraceptives (COCs): Are Bleeding Patterns Dependent on the Hormones Given?

This study has been completed.

Sponsor:

Information provided by:

Oregon Health and Science University

ClinicalTrials.gov Identifier:

NCT00120913

First received: July 12, 2005

Last updated: July 18, 2005

Last verified: July 2005

History of Changes

Purpose

While there may be a decrease in the total number of bleeding days women experience with continuous-dosed COCs (no menstrual withdrawal week), these regimens frequently result in an increased number of “breakthrough” or non-scheduled bleeding days. Breakthrough bleeding is among the main reasons cited for discontinuation of combined COCs dosed traditionally (3 weeks of active pill, 1 week of placebo) or continuously, and may offset the perceived benefit of fewer withdrawal bleeding events for many women taking continuous-dosed COCs. The exact mechanisms responsible for breakthrough bleeding patterns during hormonal contraception are unknown and may be related to the pill formulation. This study is to determine whether progestin type or estrogen dose influences bleeding patterns, side effects, or satisfaction with combined oral contraceptives (COC) dosed continuously.

Condition	Intervention
Breakthrough Bleeding	Drug: Birth control pills


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Single Group Assignment Masking: Double-Blind Primary Purpose: Prevention

Resource links provided by NLM:

MedlinePlus related topics: Bleeding

U.S. FDA Resources

Further study details as provided by Oregon Health and Science University:

Primary Outcome Measures:

Bleeding patterns

Secondary Outcome Measures:

Satisfaction, menstrual-associated symptoms


Estimated Enrollment:	160
Estimated Study Completion Date:	August 2004

Eligibility


Ages Eligible for Study:	18 Years to 49 Years (Adult)
Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Age > 18 to 49 years old
Good general health
No medical contraindications to combined COC therapy.
In addition, all participants were required to have taken cyclic COCs for at least three months at the time of enrollment, in order to avoid common transition bleeding with the initiation of COCs.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00120913

Locations


United States, Oregon
OHSU
Portland, Oregon, United States, 97239

Sponsors and Collaborators

Oregon Health and Science University

Investigators


Principal Investigator:	Alison B Edelman, MD, MPH	Oregon Health and Science University

More Information


ClinicalTrials.gov Identifier:	NCT00120913 History of Changes
Other Study ID Numbers:	OHSU IRB 7198
Study First Received:	July 12, 2005
Last Updated:	July 18, 2005
Health Authority:	United States: Institutional Review Board

Keywords provided by Oregon Health and Science University:


Breakthrough bleeding while taking continuously dosed oral contraceptives

Additional relevant MeSH terms:


Hemorrhage Metrorrhagia Pathologic Processes Uterine Hemorrhage Uterine Diseases Genital Diseases, Female	Contraceptive Agents Contraceptives, Oral Contraceptives, Oral, Combined Reproductive Control Agents Physiological Effects of Drugs Contraceptive Agents, Female

ClinicalTrials.gov processed this record on September 26, 2016

To Top